CORNELIUS JAMES M 4
4 · MBX Biosciences, Inc. · Filed Sep 17, 2024
Insider Transaction Report
Form 4
CORNELIUS JAMES M
Director
Transactions
- Conversion
Common Stock
2024-09-16+102,082→ 102,082 total - Conversion
Series B Convertible Preferred Stock
2024-09-16−233,192→ 0 total→ Common Stock (19,396 underlying) - Conversion
Series A Convertible Preferred Stock
2024-09-16−994,069→ 0 total→ Common Stock (82,686 underlying)
Footnotes (1)
- [F1]Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.